Japan's Astellas to buy U.S. drugmaker Iveric Bio for $5.9 bil.

Astellas Pharma Inc. said Monday it will buy U.S. pharmaceutical company Iveric Bio Inc. for about $5.9 billion in its largest takeover, as the Japanese drugmaker pushes ahead with its acquisition drive.Astellas will acquire all outstanding shares of Iveric Bio, which focuses on ophthalmology treatments, for $40 per share through its U.S. unit, Astellas US Holdings Inc., with the transaction expected to be completed by the end of September.Iveric Bio, which is listed on the Nasdaq market, is currently seeking U.S. approval for a drug for age-related macular degeneration, an eye disorder tha…READ FULL ARTICLE